In an SEC filing regarding its IPO, Rubius Therapeutics Inc. noted that the preclinical red cell therapeutics (RTC) work underway "will require substantial resources to demonstrate technical feasibility and establish clinical and regulatory validation," and those resources arrived as the company priced about 10 million shares at $23 each, for gross proceeds of $241.1 million.